ClinicalTrials.Veeva

Menu

Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer

Abbott logo

Abbott

Status

Completed

Conditions

Prostatic Neoplasm

Treatments

Drug: leuprolide (Lucrin/Lucrin-Tri-depot)

Study type

Observational

Funder types

Industry

Identifiers

NCT01081873
PMOS-BELG-04-001

Details and patient eligibility

About

Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOT® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the Belgian marketing authorization and reimbursement conditions.

Enrollment

2,717 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with advanced prostate cancer who have been prescribed Lucrin/ Lucrin-Tri-depot or any other treatment with local reimbursement guidelines; Patients willing to consent to data being collected and provided to Abbott Laboratories.

Exclusion criteria

  • Contraindications according to the Summary of Product Characteristics (SPC).

Trial design

2,717 participants in 1 patient group

Advanced prostate cancer participants
Description:
Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.
Treatment:
Drug: leuprolide (Lucrin/Lucrin-Tri-depot)

Trial contacts and locations

135

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems